Cardiol Therapeutics' Phase II ARCHER Trial Results to be Presented at the European Society of Cardiology Scientific Meeting on Myocardial & Pericardial Diseases
The ESC M&PD meeting brings together the world's experts working to improve the treatment of myocarditis and pericarditis. Presentation to provide comprehensive findings from the ARCHER trial following the reporting of topline results demonstrating a notable improvement in extracellular volume and a significant reduction in left ventricular mass. The Company will host a webcast conference call on Decembe
Biotechnology, Cannabis, Health, Cannabis Manufacturer
2025-11-05 7:45 AM EST | Cardiol Therapeutics Inc.
Conexeu Sciences Inc. Expands Board of Directors with the Appointments of Dr. Aaron Farberg and Dr. Sebastian Purcell
Reno, Nevada--(Newsfile Corp. - November 5, 2025) - Conexeu Sciences Inc. ("Conexeu" or the "Company"), a biotechnology innovator redefining regenerative medicine through a next-generation collagen-based platform, today announced the appointments of Aaron Farberg, M.D. and Sebastian Purcell, Ph.D. to its Board of Directors. The additions bring together leading expertise from the worlds of medicine, science, and ethics-driven innovation as Conexeu advances its mission to pioneer collagen-based
Healthcare and Hospitals, Pharmaceuticals, Health
2025-11-05 7:00 AM EST | Conexeu Sciences Inc.
MyndTec Inc. Completes Seventh Tranche of Non-Brokered Private Placement
Mississauga, Ontario--(Newsfile Corp. - November 4, 2025) - MyndTec Inc. (CSE: MYTC) ("MyndTec" or the "Company"), a neurological treatment and rehabilitation medical technology company, is pleased to announce that it has closed the seventh tranche of its non-brokered private placement previously announced on January 30, 2025 (the "Offering"). The seventh tranche of the private placement consists of 262,027 Units of the Company (the "Units") at a price of
Technology, Healthcare and Hospitals, Health
2025-11-04 6:00 PM EST | MyndTec Inc.
Medexus Schedules Second Fiscal Quarter 2026 Conference Call
Ontario and Chicago, Illinois--(Newsfile Corp. - November 4, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Thursday, November 13, 2025 to discuss Medexus's results for its second fiscal quarter ended September 30, 2025. Medexus expects to file its financial statements and MD&A after markets close on November 12, 2025. To participate in the call, please dial the following numbers:
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-11-04 5:30 PM EST | Medexus Pharmaceuticals Inc.
Hemostemix Closes Private Placement of $461,230
Calgary, Alberta--(Newsfile Corp. - November 4, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company"), the leading autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to no-option individuals suffering from pain related to angina, peripheral arterial disease, chronic limb threatening ischemia, ischemic cardiomyopathy, non-ischemic dilated cardiomyopathy, congestive heart failure, and total body
Biotechnology, Pharmaceuticals, Health
2025-11-04 3:09 PM EST | Hemostemix Inc.
BioHarvest Sciences to Host Third Quarter Earnings Call on November 13 at 4:30 p.m. Eastern Time
British Columbia and Rehovot, Israel--(Newsfile Corp. - November 4, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that it will release financial results for the third quarter ended September 30, 2025 after market close on Thursday, November 13, 2025. Management will host an inve
Biotechnology, Pharmaceuticals, Health
2025-11-04 7:30 AM EST | BioHarvest Sciences Inc.
Rise Health Nano Optics Granted Third U.S. Patent for Breakthrough Nano-Optic Technology Advancing Preventative Vision Care
Vancouver, British Columbia--(Newsfile Corp. - November 4, 2025) - Rise Health Nano Optics Inc. ("Rise" or the "Company"), a health technology innovator specializing in nano-optic solutions that effectively block wavelengths of light linked to vision stress and degenerative eye disease, is pleased to announce the granting of its third U.S. technology patent – U.S. Patent No. 12,383,955 (B2) – further strengthening its proprietary leadership position in advanced eye-protection nano
2025-11-04 7:00 AM EST | Rise Health Nano Optics
Defence Therapeutics Demonstrates Strong Preclinical in Vivo Efficacy Results Evaluating Accum-Kadcyla in Breast Cancer Models
Montreal, Quebec--(Newsfile Corp. - November 4, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company specialized in drug delivery technologies, is pleased to announce and to present today at the World ADC Conference in San Diego, USA, highly encouraging results from its latest preclinical in vivo study evaluating Accum®-Kadcyla, a novel version of Genentech/Roche's marketed ADC Kadcyla® (ado-trastuzumab
Biotechnology, Pharmaceuticals, Health
2025-11-04 3:15 AM EST | Defence Therapeutics Inc.
CardioComm Terminates Royalty Agreement and Enters into $512,000 Insider Loan Facility to Advance Gems Flex and 14-Day Holter/LTCM Platform
Toronto, Ontario--(Newsfile Corp. - November 4, 2025) - CardioComm Solutions, Inc. (TSXV: EKG) ("CardioComm" or the "Company"), a global medical provider of consumer heart monitoring and medical electrocardiogram ("ECG") software solutions, announces that it has terminated a royalty agreement announced October 1, 2025 (the "Royalty Agreement) and entered into a loan agreement dated November 3, 2025 (the "Loan Agreement") with current debt lenders to the Company (the "Lend
Technology, Healthcare and Hospitals, Health
2025-11-04 12:40 AM EST | CardioComm Solutions, Inc.
IR-MED Ltd. Announces Launch of First-in-Human Clinical Trial of Its DiaSafe(TM) Device for Diabetic Foot Ulcer (DFU) Assessment
Rosh Pina, Israel--(Newsfile Corp. - November 3, 2025) - IR-MED Ltd. (OTCQB: IRME) (the "Company" or "IR-Med"), a pioneer in artificial intelligence ("AI")-driven, non-invasive infrared spectrographic medical device develop
Technology, Biotechnology, Healthcare and Hospitals, Health
2025-11-03 4:30 PM EST | IR-MED, Inc.
Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $13.4 Million Gross Proceeds
King of Prussia, Pennsylvania--(Newsfile Corp. - November 3, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer, today announced the entry into definitive agreements to exercise certain outstanding warrants to purchase up to an aggregate of 5,663,182 shares of common stock of the Company originally issued in July 2024, December 2024, Januar
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-11-03 1:40 PM EST | Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Announces Positive Pathology Results: Final Maximum Dose Cohort for INTASYL PH-762 Skin Cancer Trial
King of Prussia, Pennsylvania--(Newsfile Corp. - November 3, 2025) - Phio Pharmaceuticals Corp. (NASDAQ
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-11-03 7:45 AM EST | Phio Pharmaceuticals Corp.
Britannia Life Sciences Inc. Enters into $11.3 Million Share Exchange Agreement with McEwen Inc. and Britannia Mining Solutions Inc.
Toronto, Ontario--(Newsfile Corp. - November 3, 2025) - Britannia Life Sciences Inc. (CSE: BLAB) ("Britannia" or the "Company") is pleased to announce that it has entered into a share exchange agreement (the "Agreement") with McEwen Inc. ("McEwen") and Britannia Mining Solutions Inc. (doing business as Paragon Geochemical Laboratories Inc.) (together, "Paragon"). Pursuant to the terms of the Agreement, McEwen will acquire 648,002 common shares of Paragon from Britannia at a deemed price
Biotechnology, Household / Consumer / Cosmetics, Health, Cannabis Ancillary Service Provider
2025-11-03 7:07 AM EST | Britannia Life Sciences Inc
Conexeu Sciences Appoints Miles Harrison as President & Chief Executive Officer, to Shape the Future of True Tissue Regeneration
Reno, Nevada--(Newsfile Corp. - November 3, 2025) - Conexeu Sciences Inc. ("Conexeu" or the "Company"), a pre-commercial biotechnology company redefining regenerative medicine through next-generation collagen science, announces the appointment of Miles D. Harrison as President & Chief Executive Officer of the Company. He has also been appointed to the Company's Board of Directors. At Conexeu, Miles will lead the Company's next phase of growth, advancing its first-in-class col
Healthcare and Hospitals, Pharmaceuticals, Health
2025-11-03 7:00 AM EST | Conexeu Sciences Inc.
Cosmo Receives CE Certification for ColonPRO EU - The Most Advanced AI Software Platform for Colonoscopy in Europe
Dublin, Ireland--(Newsfile Corp. - November 3, 2025) - Cosmo Pharmaceuticals N.V. (SIX: COPN), a global leader in AI-powered healthcare and specialty pharma, today announced that ColonPRO EU, the Company’s next-generation artificial intelligence software for colonoscopy, has received CE certification. Following FDA clearance in the United States, this certification brings to Europe the most advanced AI-assisted colonoscopy platform ever developed. The system has already
Healthcare and Hospitals, Health
2025-11-03 12:59 AM EST | Cosmo Pharmaceuticals N.V.
Mobile-health Network Solutions Reports FY2025 Results and Operational Update
Singapore, Singapore--(Newsfile Corp. - October 31, 2025) - Mobile-health Network Solutions (NASDAQ: MNDR) ("MNDR" or the "Company"), a leading AI HealthTech platform, today announced its financial results for the fiscal year ended June 30, 2025 ("FY2025"), and outlined its strategy to scale its proprietary AI-driven virtual-care platform across high-growth emerging markets. During FY2025, the Company completed its transition from an asset-heavy structure to an asset-li
2025-10-31 4:30 PM EDT | Mobile-health Network Solutions
Phio Pharmaceuticals Announces Appointment of Mr. David H. Deming to the Position of Lead Independent Director
King of Prussia, Pennsylvania--(Newsfile Corp. - October 31, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio is pleased to announce that David Deming has been appointed Lead Independent Director of the Board of Directors of Phio Pharmaceuticals. Mr. Deming brings over 30 years of experience in investment bankin
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-10-31 10:15 AM EDT | Phio Pharmaceuticals Corp.
Republic Technologies Provides Corporate Updates for Q3 and Outlooks for Q4
Vancouver, British Columbia--(Newsfile Corp. - October 31, 2025) - Republic Technologies Inc. (CSE: DOCT) (FSE: 7FM0) (WKN: A41AYF) (the "Company" or "Republic") is pleased to provide this comprehensive news release outlining recent management updates, corporate developments, and business strategies for Q2 and Q3 2025. Management Update At the Company's Annual General and Special Meeting held on August 9, 2025, Republic announced the appointment of
Technology, Pharmaceuticals, Health
2025-10-31 2:00 AM EDT | Republic Technologies Inc.
Republic Technologies gibt Unternehmensupdates für Q3 und Ausblick auf Q4 bekannt
Vancouver, British Columbia--(Newsfile Corp. - Freitag, 31. Oktober 2025) - Republic Technologies Inc. (CSE: DOCT) (FSE: 7FM0) (WKN: A41AYF) (das "Unternehmen" oder "Republic") freut sich, diese umfassende Pressemitteilung zu veröffentlichen, die aktuelle Management-Updates, Unternehmensentwicklungen und Geschäftsstrategien für das zweite und dritte Quartal 2025 zusammenfasst. Management-Update Auf der Jahres- und Sonderhauptversammlung des Unternehmen
Technology, Pharmaceuticals, Health
2025-10-31 2:00 AM EDT | Republic Technologies Inc.
Hemostemix's Boots on the Ground in Florida October Update
Calgary, Alberta--(Newsfile Corp. - October 30, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to no-option individuals suffering from pain related to angina, peripheral arterial disease, chronic limb threatening ischemia, ischemic cardiomyopathy, non-ischemic dilated cardiomyopathy, congestive heart failure, and total body ischemia, today announced major progress in Flori
Biotechnology, Pharmaceuticals, Health
2025-10-30 11:29 AM EDT | Hemostemix Inc.